Novocure Ltd Stock
€9.45
Your prediction
Financial data and news for Novocure
sharewise wants to provide you with the best news and tools for Novocure, so we directly link to the best financial data sources.
Financials
News
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable
Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society
Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
-
PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31